Currently, k-Ras (KRAS) mutation testing is recommended for CRC patients with advanced metastatic disease in order to predict the resistance to epidermal growth factor receptor (EGFR)-targeting therapy [27]. This evidence concerns the gene EGFR and metastatic neoplasm.